Talphera Q3 2026 Earnings Preview (NASDAQ:TLPH)

Talphera (TLPH) will report Q3 2026 earnings on November 12th. Analysts expect an EPS of -$0.06. The company has beaten EPS estimates 75% of the time in the past year, with 1 recent upward revision.

Original reporting
Published Nov 11, 2026, 10:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 10:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Talphera Q3 2026 Earnings Preview (NASDAQ:TLPH) — source image
Decision brief

The 30-second read

$TLPHBearishLow
01

Why it matters

The earnings preview provides the first public consensus estimate, setting expectations for the upcoming release.

02

Market read

The preview sets the market tone for TLPH and may affect related biotech stocks.

03

What to watch

Upcoming clinical trial updates or partnership news not mentioned could offset earnings disappointment.

Relevance 5/10Novelty 5/10Timing: pre‑market Thursday after earnings release

Background

Talphera is a micro‑cap biotech with a history of mixed earnings performance.

Company-level read

Ticker impact

$TLPHBearishMedium confidence
Context

Talphera (TLPH) will report Q3 earnings on Nov 12 after market close with a consensus EPS estimate of -$0.06.

Expected impact

likely pressure as the market prices in the weak EPS forecast

Evidence & confidence

Investors will react to the earnings surprise; a miss could trigger a sell‑off, while a beat may limit downside.

Market effects

Talphera operates in the biotech sector; earnings could influence peer sentiment.

US biotech market may see modest movement based on the result.

Limited to investors tracking small‑cap biotech earnings.

Counterpoint

If the company surprises to the upside, the stock could rally sharply despite the negative consensus.

Key entities

  • Talphera

    US‑listed biotech (NASDAQ:TLPH) reporting Q3 2026 earnings.

Related articles

$TLPHMed

Talphera (TLPH) Q3 2026 Earnings Call Transcript

Talphera (TLPH) reported Q3 2026 earnings, seeking FDA approval to conclude Niyad enrollment early due to 80% statistical power. They increased peak U.S. sales estimate to over $200M. Cash balance was $14.2M, with $16M in potential financing. Operating expenses rose to $3.8M from $3.3M YoY. Enrollment challenges were discussed, with no clear cause identified.

$TLPHMed

What Talphera (TLPH) Said on Its Q3 Earnings Call

Talphera (TLPH) discussed Q3 earnings, highlighting FDA submission details, increased peak-sales estimates, and cash position. The company expects $14.2M in cash and $16M in conditional financing to support operations through 2027. Expenses rose to $3.8M due to Niyad development and pre-launch activities. Talphera plans an investor event in Q1 2027 to discuss opportunities.

$TLPHMedAI 8/10

Talphera at H.C. Wainwright conference: nafamostat path gains traction

Talphera (TLPH) updated investors on its nafamostat mesylate clinical trial at the H.C. Wainwright conference. The NEPHRO study is 75% enrolled, with topline data expected in early 2025 and a potential U.S. launch in late 2025. The FDA reduced the study size to 70 patients, maintaining 90% statistical power. New guidelines recommend nafamostat, and the company sees a larger U.S. market opportunity. The stock has gained 56% over six months, with analysts setting price targets between $3 and $3.50

$TLPHMed

Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update

TALPHERA, INC. (TLPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update NEPHRO CRRT clinical study of nafamostat is 75% enrolled; expected to be complete this year Draft 2026 KDIGO guidelines added nafamostat as an acceptable CRRT anticoagulant, a posi